Results 171 to 180 of about 1,681,859 (259)

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

open access: yesPrecision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang   +7 more
wiley   +1 more source

Immunohistochemical Characterization of the Androgen Receptor in Breast Cancer and Its Relationship with Breast Cancer Subtypes. [PDF]

open access: yesMed Sci (Basel)
Sánchez-Ferrer ML   +9 more
europepmc   +1 more source

Stereotactic Prostate Cancer Ablative Re‐Irradiation: A Systematic Review and Meta‐Analysis (SPARE)

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Stereotactic ablative radiotherapy (SABR) is emerging as an alternative treatment for patients with locally recurrent prostate cancer after previous radiation. This approach allows for precise target coverage while limiting toxicity to surrounding organs.
Andre G. Gouveia   +12 more
wiley   +1 more source

Insulin‐Like Growth Factor Axis and Survival in Metastatic Hormone‐Sensitive Prostate Cancer: Post‐Hoc Analysis From the ENZAMET Phase 3 Trial

open access: yesThe Prostate, EarlyView.
ABSTRACT Background A higher ratio of IGF‐1:IGF binding protein 1 (IGFBP1) was associated with improved prognosis in the CHAARTED trial of docetaxel in participants with metastatic hormone‐sensitive prostate cancer (mHSPC). The ENZAMET trial demonstrated the survival benefit of adding enzalutamide to androgen deprivation therapy (ADT) in mHSPC, and ...
Michael A. Cilento   +15 more
wiley   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki   +6 more
wiley   +1 more source

Impact of BRCA Alterations on Androgen Receptor Pathway Inhibition Treatment Outcomes in Advanced Prostate Cancer. [PDF]

open access: yesCancer Res Commun
Chaudhary R   +8 more
europepmc   +1 more source

Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley   +1 more source

Cardiac function in zebrafish embryos is linked to an androgen receptor-adrenomedullin-proepicardium axis. [PDF]

open access: yesCell Commun Signal
Duong Phu M   +9 more
europepmc   +1 more source

Prognostic Value of MRI‐Derived Apparent Diffusion Coefficient in Intermediate‐Risk Prostate Cancer Treated With Definitive Radiotherapy

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Intermediate‐risk prostate cancer (IR‐PCa) is a heterogeneous disease with variable clinical outcomes despite established risk classification. We evaluated whether pretreatment tumor apparent diffusion coefficient (ADC) derived from multiparametric MRI was associated with long‐term outcomes and provided additional prognostic ...
Cem Onal   +4 more
wiley   +1 more source

Drugging the intrinsically disordered transactivation domain of androgen receptor. [PDF]

open access: yesSignal Transduct Target Ther
Obst JK   +14 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy